Atropine and Dexamethasone
Phase 2Small molecule
Atropine and Dexamethasone is one of 69 small molecule programs targeting Arrhythmia. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
224 competitors in Nausea and Vomiting
#DrugCompanyPhaseTrials
1Aloxi
AAvyxa
Preclinical
Alfenta
Alnylam PharmaceuticalsPreclinical
Ramosetron
AstellasPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Phenergan
BBassett Healthcare
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Cytoxan
BBaxter Healthcare Corporation
Preclinical
Adriamycin
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Nausea and vomiting1 trial
Intrathecal Dexamethasone and Atropine on Morphine Induced Post-operative Nausea and Vomiting on Caesarean Section
Completed·—·N/A·NCT05560542·150 enrolled
Arrhythmia1 trial
Brad Arrhythmia Induced by Repeated Succinylcholine During Gynecological Laparoscopic Surgery
Completed·—·Phase 2·NCT02676011·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Atropine and Dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAssiut University